Restructuring of a pharma stock

PharmaDeep value buy yields protected gains

The com­pa­ny under con­si­de­ra­ti­on bought several spe­cial medi­ca­ti­on com­pa­nies and patents but finan­ced the busi­ness with too much credit. First as a result of hiking pri­ces the stock pri­ce explo­ded. A col­laps fol­lo­wed that redu­ced the stock pri­ce well below repla­ce­ment costs. The CEO was repla­ced as well as the CFO and the com­pa­ny is stee­ring into the right direc­tion again. Extre­me moves enab­led GAMAG Black+White to imple­ment various pro­fi­ta­ble short opti­on posi­ti­ons, a way of par­ti­ci­pa­ti­on at a fur­ther dis­coun­ted pri­ce level and thus fur­ther redu­ced risk. GAMAG Black+White uses opti­on stra­te­gies exten­si­ve­ly to redu­ce and miti­ga­te risks.